# VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT01666444** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 297 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin (PLD)
- **DRUG:** VTX-2337
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01666444
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-31
- **Primary completion:** 2016-07-31
- **Final completion:** 2016-07-31
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01666444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01666444, "VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01666444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*